Gilles Gallant
Founder & Principal Consultant GG Biotech Consulting
Gilles is an oncology expert with broad biotech and pharmaceutical experience in strategic cancer drug development, evaluation, and innovations. He designed and directed global registrational and non-registrational clinical trials of Bristol-Myers Squibb oncology pipeline resulting in the worldwide approval of three indications for the blockbuster Taxol®. He led the development strategy and clinical implementation for all oncology and hematology assets at Human Genome Sciences and BioMarin Pharmaceutical leading to the approval of Talzenna™. Gilles guided the oncology, hematology and immunology in- and out-licensing activities leading the in-licensing of two oncology drug candidates, the GSK acquisition of HGS and the acquisition of talazoparib by Medivation. He led the development of the Daiichi Sankyo global oncology portfolio, including the approved Enhertu®, other ADCs, and multiple other early and late clinical stage Best-in-Class or First-in-Class oncology assets.
Seminars
Bring your burning questions to this closing panel session with the main day’s Translational Medicine speakers. Hear the presenters debate and discuss themes across clinical pharmacology and ADC dose escalation, biomarker technologies to select the right patients for the right ADC, and strategies to set up your Phase I ADC development for success
Despite ADC’s raging success as oncology therapies, translational barriers still plague bioconjugate development, with pressure to enter the clinic quickly but preclinical activity not matching early clinical readouts.
As the field turns its attention to advance more non-traditional ADC translation, join this workshop to break down best strategy to balance depth of characterization against time, contextualized with reverse translational learnings to better advance ADCs to the clinic with confidence.
Workshop highlights include:
- Leveraging reverse translation insights to streamline ADC preclinical efficacy assessment through intentional deployment of CDX and PDX models
- Understanding when and how to position toxicity assessments for an integrated and balanced picture of ADC assets
- Debating optimized strategies to balance preclinical characterization against time and cost to best advance ADCs to the clinic with confidence
- Conducting translational studies to identify biomarkers for ADC sensitivity and resistance
